Influence of PI-QUAL MRI Quality on Histopathological Up-Staging in Prostate Cancer
Overview
This study evaluated the impact of mpMRI quality, assessed by the PI-QUAL score, on the concordance between radiological staging and final pathological staging after radical prostatectomy in prostate cancer patients. Higher PI-QUAL scores correlated with improved diagnostic accuracy and reduced rates of histopathological up-staging from MRI fusion biopsy to prostatectomy results.
Background
Multiparametric MRI (mpMRI) is the gold standard for targeted prostate biopsy and tumor staging, with PI-RADS used to assess malignancy risk. However, mpMRI quality varies widely, potentially affecting diagnostic accuracy and treatment planning. The PI-QUAL scoring system was developed to standardize mpMRI quality assessment, categorizing images from non-diagnostic to optimal quality. Understanding how PI-QUAL influences staging concordance is critical for improving prostate cancer management.
Data Highlights
PI-QUAL Group
Number of Patients
Median Age (IQR)
Median iPSA (ng/ml)
Median Prostate Volume (ml)
Inadequate (1–2)
18
66 (61–72)
7.9 (5.9–12)
45 (33–64.8)
Sufficient (3)
44
66 (61–72)
7.9 (5.9–12)
45 (33–64.8)
Optimal (4–5)
287
66 (61–72)
7.9 (5.9–12)
45 (33–64.8)
Key Findings
PI-QUAL scoring categorizes mpMRI quality into inadequate (1–2), sufficient (3), and optimal (4–5) groups.
Among 349 patients, 18 had inadequate, 44 sufficient, and 287 optimal mpMRI quality.
Baseline characteristics including age, PSA levels, and prostate volume were balanced across PI-QUAL groups.
Higher PI-QUAL scores were associated with better concordance between radiological T-stage and pathological T-stage after radical prostatectomy.
Upstaging from mrT2 to pT≥3a was less frequent in patients with optimal PI-QUAL scores.
PI-QUAL assessment was performed by expert radiologists blinded to pathological outcomes, ensuring unbiased scoring.
Clinical Implications
Ensuring high-quality mpMRI as indicated by PI-QUAL scores can improve the accuracy of prostate cancer staging and reduce histopathological up-staging, thereby enhancing preoperative planning and patient counseling. Incorporating PI-QUAL assessment into routine clinical practice may help identify suboptimal imaging that could compromise diagnostic and therapeutic decisions.
Conclusion
The PI-QUAL score is a valuable tool for assessing mpMRI quality and its influence on staging accuracy in prostate cancer. Optimal mpMRI quality correlates with improved agreement between MRI-based and pathological tumor staging, supporting its integration into diagnostic workflows.
References
Giganti et al. 2020 -- Development of the PI-QUAL scoring system for mpMRI quality
European Society of Urogenital Radiology/EAU Section of Urologic Imaging consensus 2019 -- Radiological T-stage assessment
PRECISION trial -- mpMRI quality and prostate cancer diagnosis
by Maximilian Haack, Mohamad Turkman, Tobias Jorg, Lukas Müller, Gregor Duwe, Lisa Johanna Frey, Maximilian Peter Brandt, Axel Haferkamp, Hendrik Borgmann, Robert Dotzauer
